Insilico Medicine
About Insilico Medicine
Insilico Medicine leverages generative artificial intelligence and automation to accelerate drug discovery and aging-related research from discovery through development. The company operates globally with facilities in Boston, Hong Kong, Abu Dhabi, and Shanghai, focusing on AI-driven biology, target identification, and therapeutic program development through its Pharma.ai suite and science platforms like PandaOmics, Chemistry42, Generative Biologics, and inClinico. Its mission is to extend healthy longevity and sustainability by reducing time and cost to bring life-saving medications to patients. The company emphasizes multidisciplinary collaboration across biotechnology, computational biology, and translational medicine to create novel therapeutics.
Recent News
Isomorphic Labs Raises $2.1 B to Expand AI-Driven Drug Discovery Platform
Biotech’s IPO Comeback; Trump’s Tariff Loophole for Pharma
Servier Signs €1bn-Plus AI Pact with Iktos
Insilico Medicine Welcomes Dr. Halle Zhang as New Vice President of Clinical Development for Oncology
Insilico Medicine, Human Longevity Partner for Longevity Foundation Model
Insilico’s Big Gain After Hong Kong Listing: Finance Report
The Company that Built TikTok’s Algorithm Is Now Designing Drugs for Diseases Pharma Called Undruggable
STAT+: Insilico Medicine CEO on How Best to Use AI in Drug Development
AI Drug Target Platform Pairs Prediction with Benchmarking to Improve Early Discovery
Swiss Study Finds 37‑Protein Signature That Sets Centenarians Apart
Top Biotech Deals in March 2026
China Investors Energise Hong Kong Biotech Stocks. Is Foreign Money Missing Out?
Ex-CEO Behind Bars, 10x’s Clinical Ambitions, Pharma’s AI Gambit
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
METiS TechBio Raises $270M in Record HKEX AI‑Biotech IPO
Deep Generative Molecular Design and Its Value in Modern Drug Discovery (Paper Feb 26)
AI Needs a Reality Check
The Stanford Professor Behind an FDA-Cleared Cardiac AI Wants $1 Billion for His Next Company
AI Drug Discovery Is Reshaping Longevity Medicine. Is Your Practice Ready?
Insilico Medicine Launches Pharma AI Spring Kickoff 2026 Webinar
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials
ByteDance’s Anew Labs Unveils First AI‑Designed Small‑Molecule Immunotherapy
How AI Is Helping Solve the Labor Issue in Treating Rare Diseases
STAT+: Lilly’s Obesity Pill Enters the Oral GLP-1 Game, Novo Responds
Jurassic Bag: From Dinosaur DNA to Designer Goods – How Biofabrication and Automation Could Reshape Materials
Lilly Wants to Bridge Cancer Care Gap with $300M ADC Biotech Buy
METiS TechBio IPO Raises $270 M, Debuts as First Public AI‑Powered Drug Delivery Firm
Isomorphic Labs Raises $2.1 B Series B to Scale AI Drug‑Design Engine
Isomorphic Labs Secures $2.1 B Series B to Accelerate AI Drug Discovery
Longevity Science Picks up Steam in Pharma
AI Can Screen 15 Million Molecules in a Day. It Still Can’t Cure Alzheimer’s.
Insilico Medicine Secures IND for AI-Designed Rentosertib Inhalation, First Direct‑to‑Lung Trial
December 2025 Patent Highlights
Top Biotech Deals in April 2026
Insilico and Human Longevity Launch Multimillion‑dollar AI Eye‑scan to Flag Disease Years Early
From Prompt to Pill: Researchers Propose AI-Driven Path To ‘Pharmaceutical Superintelligence’
Insilico Medicine and CMS Forge Multiple Collaborations to Accelerate AI-Driven R&D in CNS and Autoimmune Disorders
Zapata Secures $15 Million Oversubscribed Funding Round to Accelerate Quantum Software Platform
Insilico’s Latest Deal Is a $120M Cardiometabolic Drug Discovery Pact with Qilu Pharma